Moderna (LTS:0A45) Change In Payables And Accrued Expense : $-430 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Moderna Change In Payables And Accrued Expense?

Moderna's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $-712 Mil. It means Moderna's Accounts Payable & Accrued Expense declined by $712 Mil from Dec. 2023 to Mar. 2024 .

Moderna's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-312 Mil. It means Moderna's Accounts Payable & Accrued Expense declined by $312 Mil from Dec. 2022 to Dec. 2023 .

Moderna Change In Payables And Accrued Expense Historical Data

The historical data trend for Moderna's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Change In Payables And Accrued Expense Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-27.00

400.00

2,069.00

24.00

-312.00

Moderna Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-594.00	-227.00	884.00	-375.00	-712.00

Moderna Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-430 Mil.

Moderna Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Moderna's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (LTS:0A45) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (LTS:0A45) Headlines

No Headlines